PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (Q46215056)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2014

Language	Label	Description	Also known as
English	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial	scientific article published in October 2014

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

object named as

G Kees Hovingh

0 references

author name string

Frederick J Raal

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Evan A Stein

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Robert Dufour

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Traci Turner

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Fernando Civeira

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Lesley Burgess

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Gisle Langslet

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Russell Scott

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Anders G Olsson

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

David Sullivan

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

G Kees Hovingh

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Bertrand Cariou

12

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ioanna Gouni-Berthold

13

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ransi Somaratne

14

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ian Bridges

15

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Rob Scott

16

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Scott M Wasserman

17

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Daniel Gaudet

18

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

RUTHERFORD-2 Investigators

19

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

language of work or name

0 references

publication date

1 October 2014

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

385

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

331-340

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

9965

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial hypercholesterolemia and coronary heart disease: a HuGE association review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61399-4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/25282519

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46215056&oldid=2100055673"